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Abstract: Neurons whose activity is regulated by glucose are found in a number of brain 
regions. Glucose-excited (GE) neurons increase while glucose-inhibited (GI) neurons 
decrease their action potential frequency as interstitial brain glucose levels increase. We 
hypothesize that these neurons evolved to sense and respond to severe energy deficit (e.g., 
fasting) that threatens the brains glucose supply. During modern times, they are also 
important for the restoration of blood glucose levels following insulin-induced 
hypoglycemia. Our data suggest that impaired glucose sensing by hypothalamic glucose 
sensing neurons may contribute to the syndrome known as hypoglycemia-associated 
autonomic failure in which the mechanisms which restore euglycemia following 
hypoglycemia become impaired. On the other hand, increased responses of glucose sensing 
neurons to glucose deficit may play a role in the development of Type 2 Diabetes Mellitus 
and obesity. This review will discuss the mechanisms by which glucose sensing neurons 
sense changes in interstitial glucose and explore the roles of these specialized glucose 
sensors in glucose and energy homeostasis. 
Keywords:  glucose-excited neurons; glucose-inhibited neurons; insulin; leptin; obesity; 
diabetes; hypoglycemia; hypoglycemia-associated autonomic failure; fasting 
 
1. Introduction 
It is clear that the brain regulates energy homeostasis. The brain responds to circulating signals of 
nutrient status and adjusts food intake accordingly [1]. The brain also receives information regarding 
peripheral adiposity stores. In response to this feedback, the brain modulates the metabolism and/or 
insulin sensitivity of a variety of tissues including liver, skeletal muscle, and adipose tissue via the 
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autonomic nervous system [2]. Thus, under normal conditions the brain senses peripheral energy status 
and responds by regulating the balance between energy intake, expenditure and storage in order to 
maintain body weight within a fairly tight range. 
The autonomic regulation of energy homesostasis involves a coordinated effort between a number 
of interconnected brain regions including, but not limited to, the hypothalamus, amygdala and 
brainstem. In addition to brain regions associated with autonomic regulation, neurocircuitry related to 
reward pathways (e.g., nucleus accumbens) is also important for regulating food intake and body 
weight [1,3]. Thus, the neural systems involved in maintaining a stable body weight are extremely 
complex and much work remains to truly understand how these disparate brain regions interact to 
control energy homeostasis. The hypothalamus, in particular, has been the focus of numerous studies 
in the past century [4]. Within the hypothalamus, the ventromedial (VMH), dorsomedial (DMH), 
lateral (LH) and paraventricular (PVH) regions have all demonstrated importance [5]. The 
ventromedial hypothalamus (VMH) which consists of the ventromedial and arcuate nuclei (VMN and 
ARC, respectively) is one key region for integrating peripheral signals of nutrient status and adiposity. 
The ARC contains the neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) neuronal populations 
which have opposing effects on energy homeostasis. NPY increases food intake and activates energy 
sparing mechanisms while melanocortins decrease food intake and increase energy expenditure [6]. 
The VMN also plays a role in regulating energy homeostasis however the exact neuronal populations 
involved are as yet unknown [4]. 
In addition to its response to circulating peptides and hormones which reflect energy status, the 
brain also senses and responds to changes in blood glucose levels. In the 1950’s, Jean Mayer’s 
glucostatic hypothesis [7] postulated that glucose receptors exist in the hypothalamus and possibly 
other central and peripheral regions known to be involved in the regulation of food intake. This 
hypothesis further stated that plasma glucose levels are sensed by these glucose receptors in the brain 
and that an increase in glucose utilization triggers meal initiation. The concept of hypothalamic 
glucose sensors has withstood the test of time. In fact, glucose sensors were first discovered in the 
VMH and LH [8,9].The question as to whether these glucose sensors control daily food intake remains 
controversial. In 1986 Campfield and Smith showed that a decrease followed by an increase in blood 
glucose levels was correlated with meal initiation [10]. Moreover, interstitial glucose levels in the 
VMH and LH vary with blood glucose concentration [11]. These data suggest that brain glucose 
sensors could regulate daily food intake. However, Levin and colleagues recently showed that there 
was no correlation between VMH glucose levels and spontaneous feeding [12]. Thus, it is unlikely that 
VMH glucose sensors regulate meal to meal food intake although it does not rule out a role for glucose 
sensors in the LH or other brain regions. Interestingly, Levin and colleagues did find that falls in VMH 
glucose concentration in response to insulin-induced hypoglycemia were correlated with increased 
food intake. This observation is consistent with the important role of the VMH in the counterregulatory 
response that restores euglycemia following insulin-induced hypoglycemia [13-15]. Thus, VMH 
glucose sensors may play a role in detecting and countering severe glucose deficit. It stands to reason 
that the brain would respond to severe glucose deficit since glucose is the primary fuel of the brain. 
Glucose sensors are located in many key areas of the brain (e.g., hypothalamus [9,16-19], nucleus 
solitarius [NTS] [20], amygdala [21]) which monitor energy status in the body and initiate appropriate 
sympathoadrenal and neurohumoral responses to maintain glucose and energy homeostasis. Glucose Sensors 2010, 10                                       
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sensors are also located in peripheral tissues including the portal and mesenteric veins [22], carotid 
body [23] and intestine [24]. Glucose sensing neurons are defined as those which alter their action 
potential frequency in response to changes in interstitial glucose levels [18,25]. The effects of glucose 
on an individual hypothalamic neuron can be either postsynaptic (e.g., direct) or via an upstream 
presynaptic neuron (e.g., indirect) [18]. There are 2 main categories of neurons whose action potential 
frequency is directly (e.g., postsynaptically) regulated by glucose; those which respond to decreases in 
interstitial glucose below 2.5 mM [18] and those which respond to increases above 5 mM [26]. Both of 
these categories of glucose sensing neurons can be further divided into 2 subtypes. Glucose-excited 
(GE) neurons increase while glucose-inhibited (GI) neurons decrease their action potential frequency 
in response to increases in interstitial glucose from 0.1 to 2.5 mM glucose [18]. Similarly, high GE 
(HGE) and high GI (HGI) neurons increase or decrease their action potential frequency, respectively, 
in response to increases in interstitial glucose from 5 to 20 mM [26]. GE neurons require glucose 
metabolism for excitation[25,27,28]; however GI neurons comprise distinct populations which either 
require glucose metabolism [27,28] or sense the glucose molecule directly [29]. Whether glucose 
sensing by HGE or HGI neurons is dependent on metabolism is unknown. 
 In this review we will focus on the metabolically sensitive VMH GE and GI neurons as prototype 
glucose sensors for two reasons. First, VMH GE and GI neurons have been more thoroughly 
characterized in comparison to either the HGE/HGI neurons or glucose sensing neurons in other brain 
regions. Second, the glucose sensitivity of VMH GE and GI neurons lies within the range of interstitial 
glucose concentrations found within the majority of the brain in vivo under physiological and 
pathophysiological conditions (i.e., 0.2 to 5 mM) [30-33]. The evidence that interstitial brain glucose 
levels are approximately 30% of those found in the blood is as follows. Using a glucose oxidase 
electrode implanted in the VMH Silver and Erecinska demonstrated that at 7.6 mM plasma glucose in 
a fed anesthetized rat, interstitial VMH glucose was only 2.5 mM. Decreasing plasma glucose   
to 2–3 mM or increasing to 15 mM, resulted in brain glucose levels of 0.16 mM and 4.5 mM, 
respectively [11,34]. Although these studies were performed in anesthetized animals, they are 
consistent with recent studies in conscious animals. Using the zero net flux method for microdialysis, 
DeVries  et  al. show that VMH glucose levels were approx 1.5 mM in fed unanesthetized rats   
and 0.7 mM after an overnight fast [35]. Interestingly, using similar techniques, McNay and colleagues 
have shown that brain glucose levels vary with rat strain, brain region, and neuronal   
activity [36-39]. However, all of these studies consistently indicate that physiological levels of glucose 
within the brain vary within a fairly tight range from 0.7 to 2.5 mM. In fact, even though the ARC lies 
near the median eminence where the blood brain barrier is “leaky”, Dunn-Meynell et al. found that 
ARC interstitial glucose levels are indistinguishable from the rest of the VMH [12]. On the other hand, 
interstitial brain glucose levels below 0.7 mM and above 2.5 mM are associated with pathological 
hypo- and hyperglycemia, respectively [11]. Both VMH GE and GI neurons are extremely sensitive to 
glucose changes under 2 mM, with minimal response above 2 mM suggesting that these glucose 
sensing neurons primarily sense glucose deficit [30,31]. It is unclear whether brain glucose levels ever 
exceed 5 mM in the presence of an intact blood brain barrier. This raises questions about the 
physiological significance of HGE and HGI neurons. However, it should be noted that hyperglycemia 
impairs the integrity of the blood brain barrier [40]. Thus, these glucose sensing subtypes could 
contribute to hyperglycemia-associated pathology. Sensors 2010, 10                                       
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Therefore, the purpose of this review is to put forward the hypothesis that VMH glucose sensing 
neurons are part of a safety network which protects the brain against severe energy deficit. This 
hypothesis posits that glucose sensing neurons evolved as a defense against famine. In the modern 
world, they would also be important for restoring euglycemia following iatrogenic insulin-induced 
hypoglycemia. On the other hand, it would not be energetically efficient if small meal to meal changes 
in glucose levels altered the systems responsible for protecting the brain against the dangers of 
hypoglycemia. Thus, this hypothesis further posits that during normal energy homeostasis it would be 
important that these glucose sensing neurons do not respond to small glucose decreases associated with 
meal to meal fluctuations in blood glucose and activate the powerful homeostatic systems present in 
the VMH. This hypothesis leads to the prediction that obesity and type 2 diabetes mellitus (T2DM) are 
associated with a hypersensitivity of glucose sensing neurons to small glucose reductions. If glucose 
sensing neurons became overly sensitive to decreased glucose it could lead to an inappropriate signal 
in the brain of energy deficit. This would lead to activation of energy sparing mechanisms during 
conditions of energy sufficiency (or excess) in order to compensate for the perceived deficit. Such 
compensation could contribute to the development or exacerbation of obesity and T2DM. In support of 
this hypothesis, Colombani et al. recently showed that injection of a low glucose concentration into the 
carotid artery toward the brain caused a greater increase in VMH neuronal activity in obese fa/fa 
Zucker rats compared to their lean counterparts. This carotid glucose injection did not change 
peripheral glucose levels and thus reflects a central increase in sensitivity to glucose deficit in a rodent 
model of T2DM [41]. 
The following review is designed to evaluate the literature supporting such a role for VMH glucose 
sensing neurons. In order to accomplish this goal, it will first describe VMH glucose sensing neurons 
and the mechanisms by which they sense glucose. The role of VMH glucose sensing neurons during 
energy deficit (i.e., fasting, insulin-induced hypoglycemia) will then be discussed. Next, changes in 
VMH glucose sensing neurons during T2DM will be described. Finally, the data will be summarized 
and interpreted with regard to the proposed hypotheses. 
2. Glucose Sensing Neurons 
2.1. GE Neurons 
GE neurons have been identified in the ARC and VMN [9,18,25,30,31,42]. Like the pancreatic -cell, 
VMH GE neurons utilize the ATP-sensitive potassium (KATP) channel to sense glucose. This was first 
demonstrated by Ashford and colleagues using single channel and whole cell patch-clamp   
recording techniques [17,25,43]. Many investigators using a variety of experimental approaches 
including molecular biology, pharmacology and transgenic animal models have corroborated these  
findings [18,28,30,44,45]. The concentration-response relationships for both KATP channel currents and 
action potential frequency of VMH GE neurons reveal a very steep and virtually linear relationship for 
glucose concentration and neuronal activity between 0.1 and 1.5 mM glucose. The slope of the curve 
then decreases sharply and plateaus between 2.5 and 5 mM glucose [30]. These data strongly suggest 
that the KATP channel on GE neurons plays a role in physiological brain glucose sensing. Moreover, 
they support a role for VMH GE neurons in the detection of energy deficit. Sensors 2010, 10                                       
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Pancreatic -cells and GE neurons share several other components of glucose sensing. For example, 
the glucose transporter 2 (GLUT2), as well as glucokinase (GK), the rate limiting enzyme for 
glycolysis, are expressed in both GE neurons and -cells [27,28,46]. Like the -cell, GK plays a clear 
role in glucose sensing in GE neurons [27,28,46]. However, while KATP channels are expressed in all 
GE neurons, only approximately half of VMH GE neurons express GK and approximately 30% 
express GLUT2 [28]. Approximately half of VMH GE neurons also express the insulin sensitive 
glucose transporter, GLUT4 [28]. Claret et al. have shown that transgenic mice lacking the 2 subunit 
of AMP-activated protein kinase (AMPK), an important cellular fuel gauge, also lack ARC GE 
neurons [47]. However, we found that acute pharmacological activation or inhibition of AMPK had no 
effect on glucose sensing in VMH GE neurons [48]. These data suggest that multiple subtypes of GE 
neurons may exist which utilize alternate glucose sensing strategies. 
The peptide phenotype of ARC and VMN GE neurons remains controversial. As mentioned 
previously, the ARC contains several important cell populations which play a role in the regulation of 
energy balance. ARC POMC and NPY neurons play a reciprocal role in energy homeostasis. 
Activation of POMC neurocircuitry favors decreased food intake and increased energy expenditure. In 
contrast, NPY leads to increased food intake and decreased energy expenditure [1]. Several studies 
support the hypothesis that GE neurons belong to the ARC POMC population. Electrical activity of 
POMC neurons is correlated with changes in energy status [49]. Both Ibrahim et al. and Claret et al. 
have demonstrated that POMC neurons were GE neurons using a transgenic mouse in which the 
POMC promoter was labelled with green fluorescent protein (GFP) although the glucose 
concentrations used by Ibrahim et al. were supra-physiologic [47,50]. On the other hand, several 
observations indicate that POMC neurons are not GE neurons. First, GE neurons are not present in the 
region of the ARC considered the location of the POMC neurons in either rats or wild-type mice. 
Rather, VMH GE neurons are concentrated in the cell-poor region located between the ARC and the 
VMN along the ventrolateral border of the VMN (VL-VMN) [30,48]. Second, immunohistochemical 
evaluation following electrophysiological recording in brain slices from rats has shown that GE 
neurons which respond to changes in interstitial glucose below 2.5 mM are not POMC neurons [30]. 
Moreover, POMC neurons from a different strain of POMC-GFP mouse than that used above were not 
glucose sensing [51]. Finally, glucose injection into the carotid artery did not increase levels of the 
marker of neuronal activation, cfos, in POMC neurons [51]. Whether these discrepancies represent 
differences between rat and mouse or between strains of transgenic mice remains to be determined 
before one can clearly conclude that POMC neurons are GE neurons. However, VMH GE neurons are 
involved in the NPY-POMC signalling network since NPY inhibits while melanocortin stimulating 
hormone (MSH) stimulates GE neurons [30]. 
Although the phenotype of GE neurons remains elusive, the observation that these neurons are 
concentrated in the VL-VMN supports a role for these neurons in metabolic regulation. In the 1940s it 
was found that specific lesions which include the VL-VMN and the capsule surrounding the VMN 
cause the most profound obesity [52]. Later studies further support a critical role for this region in the 
regulation of energy balance. The neurotoxin gold-thioglucose which causes obesity and T2DM 
destroys neurons specifically in the VL-VMN and the “cell-poor” region between the VMN and   
ARC [53]. Moreover, many VMH efferent projections to other brain regions involved in metabolic 
regulation arise from the VL-VMN. A full discourse on the VL-VMN is beyond the scope of this Sensors 2010, 10                                       
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review. However, an excellent and comprehensive review by Bruce M. King
 carefully evaluates the 
role of the VL-VMN in the regulation of energy balance in composite data dating to 1940 [4]. Because 
specific lesions of the VL-VMN cause obesity this area mostly likely supports increased energy 
expenditure and decreased energy storage. Unfortunately, due to a lack of anatomical markers and a 
full understanding of neuronal circuitry, the VL-VMN has been sorely neglected in recent years. 
However, clearly GE neurons are concentrated in a region of the VMH which has a well established 
role in the regulation of energy homeostasis. 
In addition to being located in a region which is critical for energy homeostasis, VMH GE neurons 
are regulated by the peripheral adiposity signals, insulin and leptin. Leptin is a hormone secreted from 
white adipose tissue in proportion to the amount of adipose stores. Insulin levels, in addition to being 
regulated by blood glucose, also rise with adiposity. Both leptin and insulin play important roles in the 
endocrine feedback loop to the hypothalamus which signals the brain that peripheral energy stores are 
sufficient. Moreover, POMC neurons are activated and NPY neurons are inhibited by leptin and 
insulin. Thus, increased leptin and insulin levels decrease food intake and body weight [2].   
Spanswick et al. found that insulin had a profound inhibitory effect on the activity of GE neurons due 
to KATP channel activation [42]. In contrast, while insulin still opened the KATP channel in 2.5 mM 
glucose, this change in conductance was insufficient to alter action potential frequency [48]. The lack 
of effect of insulin on action potential frequency in 2.5 mM glucose does not mean that insulin does 
not exert a physiological effect on GE neurons. Rather it suggests that under physiological conditions 
insulin regulates the responsiveness of GE neurons to presynaptic input or changes in the interstitial 
milieu. Insulin activation of KATP channels would increase whole cell conductance making it less likely 
that other inputs (or changes in glucose) would alter GE neuron’s membrane potential. Our recent data 
showing that insulin prevents GE neurons from detecting decreased interstitial glucose via the 
phosphoinositol-3-kinase (PI3K) signaling pathway support this concept [48]. Furthermore, these data 
are consistent with our hypothesis that under conditions of energy sufficiency, when insulin is present, 
the ability of GE neurons to sense decreased glucose would be masked. On the other hand, when 
insulin levels are low (e.g., after a fast) or when insulin resistance is present, GE neurons may respond 
to glucose decreases. 
Leptin also regulates the activity of some GE neurons. Similar to their observations with insulin, 
Spanswick et al. showed that leptin in 10 mM glucose caused complete inhibition of VMH GE neurons 
by opening KATP channels [54]. However, in 2.5 mM glucose VMH GE neurons have a heterogeneous 
response to leptin, with some showing no response and others being inhibited [30] or excited [55]. 
These data suggest that not all GE neurons have leptin receptors. Indeed, while leptin receptors are 
abundant in the ARC and dorsomedial VMN, they are sparse in the lateral VMN [56]. Such a 
conclusion is again consistent with multiple subtypes of GE neurons. The effect of leptin on the 
glucose sensitivity of GE neurons has not yet been evaluated. However, both insulin and leptin open 
KATP channels on hypothalamic neurons via the PI3K signaling pathway [57]. Thus, we might predict 
that leptin also attenuates the response of certain populations of GE neurons (at least those which 
possess leptin receptors) to decreased glucose. 
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2.2. GI Neurons 
Some of the components of glucose sensing in GI neurons are similar to those found in GE neurons. 
For example, Levin and colleagues have demonstrated a clear role for GK in VMH GI   
neurons [27,28,46]. Similarly, both GLUT2 and GLUT4 are expressed in a portion of VMH GI 
neurons [28]. However, the signal transduction pathway by which changes in intracellular ATP alter 
the activity of VMH GI neurons is completely distinct. 
We have recently described the signaling pathway by which decreased glucose activates VMH GI 
neurons in detail [58]. This signaling pathway is shown in Figure 1A. The first step involves activation 
of the 2 subunit of AMPK. AMPK is a heterotrimeric protein which is activated by an increase in the 
AMP:ATP ratio, as well as by several upstream kinases including the tumor suppressor, LKB-1, and 
Ca
2+/calmodulin dependent protein kinase (CaMKK), [59,60]. AMPK activation turns on catabolic 
processes which generate ATP while turning off anabolic ATP consuming processes. A role for 
AMPK in energy balance is well established (for review see [60]). Hypothalamic AMPK is a target for 
a number of hormones and transmitters which regulate energy balance [61-65]. Pharmacological 
activation of hypothalamic AMPK increases food intake [66]. Thus, it is not surprising that decreased 
glucose activates AMPK in GI neurons. 
Figure 1. Regulation of the glucose sensitivity of NPY-GI neurons in fed and fasted conditions. 
 
Decreased interstitial glucose levels are translated into decreased intracellular glucose levels resulting in an 
increased AMP/ATP ratio. Increased AMP/ATP activates AMPK which enhances NO-sGC-cGMP signaling. 
Increased levels of cGMP are needed for full AMPK activation and closure of the CFTR chloride 
conductance in response to decreased glucose. CFTR closure leads to depolarization and increased action 
potential frequency. In the fed state, elevated leptin levels cause tonic inhibition of AMPK and attenuation of 
the response of GI neurons to decreased glucose. Insulin levels are also elevated in the fed state. Insulin 
increases nNOS activation via PI3K which could lead to enhanced responses to decreased glucose. It is also 
possible that insulin may inhibit AMPK in GI neurons since this effect of insulin has been demonstrated in 
hypothalamic tissue. AMPK inhibition would contribute to a low sensitivity to glucose decreases. However, 
the effects of insulin on the glucose sensitivity of GI neurons have not yet been evaluated. In the fasted state, 
both leptin and insulin levels are reduced. The reduction in leptin-induced AMPK inhibition leads to an 
enhanced response of GI neurons to decreased glucose. Whether insulin contributes to or opposes this change in 
glucose sensitivity is not known. Abbreviations: NPY (neuropeptide Y), GI (glucose-inhibited), AMPK (AMP-
activated protein kinase), sGC (soluble guanylyl cyclase), cGMP (cyclic GMP), CFTR (cystic fibrosis 
transmembrane regulator), PI3K (phosphatidylinositol-3-kinase). Sensors 2010, 10                                       
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The next step in glucose sensing by GI neurons involves an interaction between AMPK and the 
gaseous messenger, nitric oxide (NO) [58]. VMH AMPK activation phosphorylates neuronal NO 
synthase (nNOS) leading to NO production in GI neurons [67]. NO, in turn, further activates AMPK 
via the NO receptor soluble guanylyl cyclase (sGC) which increases cyclic GMP (cGMP) levels. 
Amplification of AMPK activation by the sGC-cGMP pathway is necessary for depolarization of GI 
neurons in response to decreased glucose [58]. Such an interaction has also been described in skeletal 
muscle [68] and vascular endothelial cells [69]. In endothelial cells cGMP activates the upstream 
AMPK kinase, CaMKK. CaMKK further activates AMPK for a full biological effect [69]. These data 
lead to the hypothesis that, as in endothelial cells, the NO signaling pathway in GI neurons activates an 
upstream AMPK kinase such as CAMKK. AMPK kinase activation increases the sensitivity of AMPK 
for AMP [65]. Thus, the NO signaling pathway may be a critical determinant of the glucose sensitivity 
of GI neurons. 
As mentioned above role for AMPK in energy balance is well established [64,65,70-72]. Although 
less lauded, NO strongly deserves consideration. NO is a unique neurotransmitter due to its ability to 
diffuse across cell membranes [73]. Furthermore, nNOS is a potential site whereby many 
neurotransmitters and hormones could influence the glucose sensitivity of GI neurons. nNOS activity 
is dependent on, and enhanced by intracellular calcium increases which are spatially localized to this 
enzyme [74]. Thus, any neurotransmitter which is linked to a calcium permeable ion channel or 
increases calcium release from internal stores in such a way to spatially engage nNOS could potentially 
enhance the response of GI neurons to decreased glucose. nNOS is also a target of a number of 
hormones, including leptin and insulin [67]. Moreover, a number of observations suggest that NO 
regulates energy balance. Orexin-, ghrelin- and NPY-induced feeding are NO dependent [75-77]. NOS 
activity and expression are elevated in obese ob/ob mice which lack the leptin receptor, and NOS 
inhibition decreases food intake and body weight in these animals [78]. This latter observation 
supports our hypothesis that under normal energy status, it is important that glucose sensing neurons 
do not respond to small changes in interstitial glucose. However, during diabetes these neurons may 
become sensitized to glucose decreases. NO-mediated increases in the sensitivity of AMPK for AMP 
would enhance the response of GI neurons to glucose decreases. Thus, NOS inhibition would be 
expected to normalize food intake and body weight in ob/ob mice. The in vivo data of Colombani et al. 
showing increased neuronal activation in response to low glucose in fa/fa Zucker rats, which have a 
dysfunctional leptin receptor, are consistent with the hypothesis that GI neurons have an enhanced 
response to glucose decreases in T2DM [41]. 
The last step in the response of VMH GI neurons to decreased glucose involves closure of a 
chloride channel [18,51]. We hypothesize that the identity of this chloride channel is the cystic fibrosis 
transmembrane regulator (CFTR) [51,58]. AMPK phosphorylates and inhibits the CFTR [79]. 
Gemfibrozil, which selectively binds the CFTR, blocks the effects of low glucose by opening a 
chloride channel [51,58]. Furthermore, decreased glucose, AMPK activation and the cell permeable 
cGMP analog, 8-bromo-cGMP all increase VMH CFTR phosphorylation, while nNOS inhibition 
blocks CFTR phosphorylation in response to decreased glucose [58]. However, gemfibrozil has been 
reported to have opposing effects on the peripheral CFTR [80]. Moreover, while AMPK 
phosphorylates and inhibits the CFTR [79], phosphorylation is not always correlated with channel 
closure [81]. Thus, further studies are needed to confirm a role for the CFTR as the specific channel Sensors 2010, 10                                       
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mediating glucose sensing by VMH GI neurons. Interestingly, there is a high incidence of diabetes 
among patients with cystic fibrosis; however it is not clear whether this is due entirely to peripheral 
CFTR dysfunction or whether there is a central component [82-85]. 
Like GE neurons, leptin and insulin regulate VMN GI neurons. Insulin increases NO production by 
VMH GI neurons via the PI3K signaling pathway [67]. In contrast, leptin inhibits NO production in 
VMN GI neurons in 2.5 mM glucose by inhibiting AMPK [33]. Leptin also attenuates the response of 
GI neurons to decreased glucose. The AMPK activator, 5-aminoimidazole-4-carboxamide-1-b-4-
ribofuranoside (AICAR), blocked leptin’s effect on the glucose sensitivity of GI neurons. Moreover, 
leptin prevents the increase in VMH AMPK2 phosphorylation in response to decreased glucose [33]. 
This is consistent with reports by others showing that leptin inhibits hypothalamic AMPK activity [64]. 
The effect of insulin on glucose sensitivity of GI neurons has not been evaluated. Since insulin 
increases NO production in GI neurons, it is possible that insulin enhances their response to decreased 
glucose. On the other hand, insulin hyperpolarizes GI neurons possibly by activating KATP 
channels  [31,67]. This latter effect may attenuate activation in response to decreased glucose. To 
further complicate the matter, insulin has also been shown to inhibit hypothalamic AMPK [64]. Thus, 
it is difficult to predict insulin’s effect on glucose sensitivity. However, our observation that leptin 
blocks the response to decreased glucose is again consistent with our overall hypothesis that under 
conditions of energy sufficiency (e.g., in the presence of leptin) the ability of GI neurons to sense 
glucose decreases is blocked. 
3. Glucose Sensing Neurons and Energy Deficit 
3.1. Fasting 
It is well established that the ARC NPY neurons which project to the PVN [86] as well as the spinal 
cord [5]
 stimulate food intake and decrease energy expenditure. Approximately 40% of NPY neurons 
are GI neurons [33,51,87]. Moreover, fasting enhances both the response of VMH GI neurons and 
NPY release to glucose decreases [33]. Thus, the stimulatory effect of fasting on NPY release is 
mediated, in part, by changing the glucose sensitivity of NPY-GI neurons such that they are activated 
by smaller glucose decreases. AMPK activation shifts the glucose sensitivity of GI neurons from fasted 
animals to that seen in GI neurons from fed animals while AMPK inhibition does the converse [33]. 
Leptin inhibits hypothalamic AMPK and the response of VMH GI neurons to decreased   
glucose [33,64]. Thus, decreased leptin levels during fasting may contribute to the enhanced response 
of NPY-GI neurons to decreased glucose by releasing the normal AMPK inhibition [1,64]. Figure 1 
illustrates the hormonal regulation of GI neurons in the fed and fasted state. These data suggest that 
NPY-GI neurons release more NPY in response to glucose deficit when peripheral energy stores (e.g., 
glycogen) are depleted. Thus, in the fasted state where brain energy levels are diminished and leptin 
levels are low, glucose deficit activates NPY-GI neurons to a greater extent. Increased activation of 
NPY-GI neurons may lead to increased food intake and decreased energy expenditure in order to 
restore energy balance. However, if this system were inappropriately activated during energy 
sufficiency, it could also contribute to the development of T2DM and obesity.  
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3.2. Hypoglycemia Detection and the Counterregulatory Response (CRR) 
Intensive insulin therapy prevents the deleterious effects of hyperglycemia in Type 1 (T1) and 
advanced T2DM. The major side effect of intensive insulin therapy is hypoglycemia. Powerful 
neuroendocrine and autonomic counterregulatory responses (CRR) that prevent and correct 
hypoglycemic conditions protect the brain from hypoglycemia [88,89]. The CRR involves the release 
of glucagon, epinephrine and corticosterone. Together these hormones restore euglycemia. However, 
these mechanisms can become impaired as a result of recurrent hypoglycemic episodes, leading to a 
life-threatening condition known as hypoglycemia-associated autonomic failure (HAAF). During 
HAAF, the glycemic threshold for the CRR shifts to lower glucose levels and the mechanisms that 
provide warning signals of impending hypoglycemia (increased sweating, confusion, etc.) become 
severely impaired. As a result, glucose levels are allowed to drop, without detection, to dangerously 
low or lethal levels [88]. There are significantly more episodes of severe hypoglycemia in T1DM. 
However, hypoglycemic episodes are on the rise in T2DM and the risk of severe hypoglycemia 
increases with duration of the disease [90-92]. Thus, recurrent hypoglycemia is currently a major 
limiting factor in the management of T1 and T2DM. 
Glucose sensors in the portal vein, the brainstem and the VMH have all been linked to 
counterregulatory responses to hypoglycemia and/or glucoprivation [14,93-95]. The relative roles of 
these regions in the CRR are still not completely understood. The rate of glucose decline may 
determine whether peripheral or central sensors predominate. When glucose levels decrease rapidly, 
central sensors appear to play the dominate role whereas the response to a slower decline is mediated 
by glucose sensors in the portal and mesenteric veins [93]. In humans with T1DM, glucose declines 
occur at variable rates during a 24 hour period. Hypoglycemia develops more slowly overnight or in 
response to basal insulin replacement but can be rapid after meals especially with exercise and/or 
rapidly acting insulin analogues (R. McCrimmon, University of Dundee, Scotland UK, personal 
communication). This suggests that both central and peripheral glucose sensors play a role in the 
response to hypoglycemia. Moreover, it is likely that the initiation of the CRR involves integration 
between multiple brain and peripheral sensors [96]. The range of glucose concentrations to which 
VMH GI and GE neurons respond suggest that they sense glucose deficit [18,30]. Thus, glucose 
sensing neurons may play a role in protecting the brain against dangerous glucose decreases. 
Observations showing that the ability of VMH GI and GE neurons to sense decreased glucose is 
impaired under a number of conditions in which the ability of the brain to mount the CRR is also 
impaired support a role for these neurons in hypoglycemia detection and the CRR. First, as mentioned 
above, recurrent hypoglycemia impairs the CRR and produces HAAF. The ability of VMH GI and GE 
neurons to sense glucose decreases is also attenuated by recurrent hypoglycemic episodes [32,97,98]. 
Second, VMH Injection of the corticotrophin-releasing factor 2 receptor agonist, urocortin, impairs the 
CRR in vivo and urocortin incubation in vitro attenuates the response of VMH GI and GE neurons to 
decreased glucose [95]. Third, VMH lactate infusion also impairs the CRR [99]. When glucose is 
lowered in the presence of lactate, VMH GI neurons have a blunted response to decreased glucose (GE 
neurons have not yet been evaluated) [32]. Finally, VMH NO signaling is necessary for both the full 
generation of the CRR and glucose sensing by VMH GI neurons. VMH NOS inhibition in vivo and 
nNOS inhibition in vitro impair the CRR and the response of GI neurons to decreased glucose, Sensors 2010, 10                                       
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respectively [58,100]. Interestingly, the CRR is impaired and VMH GI neurons are completely absent 
in mice lacking nNOS [100]. Similarly, T1DM is associated with an impaired CRR and VMH GI 
neurons from T1DM rats neither produce NO nor depolarize in response to decreased 
glucose [36,101]. Together, these data provide strong evidence that VMH GI and GE neurons play a 
role in hypoglycemia detection. Moreover, these data indicate that alterations in the glucose sensitivity 
of VMN glucose sensing neurons may contribute to HAAF. 
Figure 2. Hypothetical mechanism underlying effects of recurrent hypoglycemia on the 
glucose sensitivity of VMH GI neurons.  
 
 
Acute hypoglycemia (A) leads to activation of AMPK and the NO-sGC-cGMP signaling pathway. cGMP 
further activates AMPK leading to closure of the CFTR, depolarization and increased action potential 
frequency. Hypoglycemia also increases ROS levels. The combination of NO and ROS production may cause 
S-nitrosylation of nNOS and sGC. S-nitrosylation of these enzymes leads to a decrease in their activity and a 
reduction in NO signaling. Therefore, recurrent hypoglycemia (B) would lead to decreased sensitivity of GI 
neurons to reduced glucose. Abbreviations: VMH (ventromedial hypothalamus), GI (glucose-inhibited), 
AMPK (AMP-activated protein kinase), sGC (soluble guanylyl cyclase), cGMP (cyclic GMP), CFTR (cystic 
fibrosis transmembrane regulator), ROS (reactive oxygen species). 
 
The mechanism by which hypoglycemia impairs VMH GI and GE neurons glucose sensitivity is not 
known. One possibility is that hypoglycemia increases nutrient flux in neurons and masks glucose 
deficit [102-106]. Alternatively, hypoglycemia may impair glucose responsive signaling by glucose 
sensing neurons. One mechanism by which this may occur in GI neurons is the production of reactive 
oxygen species (ROS). For example, insulin-induced hypoglycemia increases brain ROS levels [107]. 
When NO is produced in the presence of ROS there is an increase in S-nitrosylation of a number of 
proteins including sGC and nNOS [108]. S-nitrosylation of these enymes decreases their   
activity [109,110]. As discussed above, impaired NO signaling prevents GI neurons from sensing 
glucose deficit. This hypothesis which is illustrated in Figure 2 is consistent with the observation that 
RH decreases nNOS activity [98]. Our preliminary data showing that preventing ROS production 
during insulin-induced hypoglycemia prevents the subsequent development of HAAF provide further 
support for this hypothesis [111]. Clearly much more work needs to be done to understand how 
hypoglycemia impairs central glucose sensing. Understanding the mechanisms by which VMN GSNs 
detect hypoglycemia and their dysfunction after recurrent hypoglycemia will facilitate development of Sensors 2010, 10                                       
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appropriate treatments for diabetes aimed at maintaining tight glycemic control while reducing the 
incidence of inadvertent hypoglycemia. 
An interesting and unanswered question relates to the specific aspects of the CRR affected by GI 
and/or GE neurons. GI neurons are a heterogeneous population in that 40% of ARC NPY neurons are 
GI neurons [33,51,87]. However VMN GI neurons are obviously not NPY neurons since this 
phenotype does not exist in the VMN [112]. Studies of NPY KO mice showed that feeding in response 
to insulin-hypoglycemia was absent however hormonal counterregulation was unaltered [113]. This 
suggests that the NPY-GI neurons may belong to the population of NPY neurons which project to the 
PVH and play a role in food intake [112]. nNOS-KO mice that lack GI neurons in the mediobasal 
hypothalamus (ARC + VMN) showed significantly decreased epinephrine (but not glucagon) 
responses to hypoglycemia suggesting that VMN GI neurons are involved in the sympathoadrenal 
cCRR [100]. It is possible that the glucagon response was not significantly impaired in these animals 
due to the presence of normal GE neurons. We have shown that GE, as well as GI, neurons are 
impaired under conditions where both epinephrine and glucagon responses to hypoglycemia are 
impaired [32,98]. Taken together, these data suggest that different populations of glucose sensing 
neurons may play distinct roles in the CRR. However, it is clearly premature at this point to go beyond 
casual speculation.  
4. Glucose Sensing Neurons and T2DM 
T2DM is associated with central insulin and leptin resistance [114,115]. Insulin and leptin prevent 
VMH GE and GI neurons, respectively, from sensing glucose deficit [33,48]. Thus, it is logical to 
hypothesize that VMH glucose sensing neurons might be inappropriately responsive to glucose 
decreases during T2DM. This is now known to be true for VMH GE neurons [116]. GE neurons from 
diabetic Zucker fa/fa rats are insensitive to the effects of insulin on neuronal activity [42]. Similarly, 
VMH GE neurons from diabetic db/db mice respond to glucose decreases in the presence of insulin, 
while VMH GE neurons from wild-type mice do not. Moreover, the baseline response of VMH GE 
neurons from db/db mice to glucose decreases is enhanced compared to VMH GE neurons from   
wild-type control mice. Both baseline glucose sensitivity as well as the effect of insulin on VMH GE 
neurons from db/db mice is restored by the insulin sensitizer, Compound 2. The effects of Compound 2 
are blocked by PI3K inhibition [116]. This latter observation is consistent those indicating that T2DM 
is associated with dysfunctional hypothalamic PI3K signaling [2]. Thus these data support our 
hypothesis that GE neurons have an enhanced response to decreased glucose in T2DM. The regulation 
of the glucose sensitivity of VMH GE neurons by insulin is illustrated in Figure 3. 
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Figure 3. Hormonal Regulation of the glucose sensitivity of VMH GE Neurons. 
 
Hormonal regulation of the glucose sensitivity of VMH GE neurons in controls (A) and T2DM (B). 
Decreased interstitial glucose levels are translated into decreased intracellular glucose. This decreases the 
ATP/ADP ratio, opens the KATP channel and hyperpolarizes the cell leading to a decrease in action potential 
frequency. Insulin, via PI3K, attenuated KATP activation in response to decreased glucose. Since PI3K also 
mediates leptins effects on GE neurons, it is possible that leptin similarly reduces GE responses to decreased 
glucose however this has not been tested. Moreover, leptin is known to have pleiotropic effects on VMH GE 
neurons. In T2DM, insulin resistance leads to an increased responsiveness of GE neurons to glucose 
decreases which is normalized by enhancing PI3K signaling. Whether leptin resistance during T2DM 
contributes to enhanced responses of GE neurons to decreased glucose remains to be tested. Abbreviations: 
VMH (ventromedial hypothalamus), GE (glucose-excited), T2DM (type 2 diabetes mellitus), KATP (ATP-
sensitive potassium channel), PI3K (phosphatidylinositol-3-kinase). 
 
At this time it is not possible to determine with any certainty whether altered glucose sensing in GE 
neurons is a contributing factor in the development of T2DM or whether it results from T2DM. 
However, there is some evidence supporting a causal role for GE neurons in the development of 
T2DM and obesity. Rats that are predisposed to develop diet-induced obesity (DIO) have a   
pre-existing impairment in hypothalamic insulin and leptin sensitivity [117,118]. Moreover, reducing 
hypothalamic PI3K activity leads to reduced energy expenditure and weight gain [119]. These data 
suggest that deficits in hypothalamic insulin signaling, and thus impaired glucose sensing in GE 
neurons may precede the development of obesity and diabetes. One caveat that should be mentioned 
with regard to our hypothesis is that Levin et al. showed that the increase in fos-like immunoreactivity 
in response to glucose is reduced in DIO-prone rats compared to those rats which resist DIO [120]. 
However, this study specifically investigated increased glucose whereas the present hypothesis is 
related to responses to decreased glucose. Moreover, GE neurons themselves show very little response 
above 2.5 mM glucose, so it is possible that the glucose-induced neuronal activation in response to 
elevated glucose in these rats was due to a different population of glucose sensing neurons. 
The role of GI neurons during T2DM is difficult to predict. Colombani et al. recently showed that 
low glucose injected toward the brain increased ARC electrical activity to a greater extent in fa/fa 
Zucker rats compared to their lean counterparts [41]. This is consistent with enhanced responses of GI 
neurons to decreased glucose. Furthermore, leptin clearly attenuates the response of GI neurons to 
decreased glucose [33]. Thus, leptin resistance in DIO-prone or Zucker fa/fa rats could cause enhanced 
responses of VMH GI neurons to decreased glucose. On the other hand, the CRR and the response of 
GI neurons to decreased glucose were attenuated in the neuronal insulin receptor knockout (NIRKO) Sensors 2010, 10                                       
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mouse [121]. This discrepancy may reflect the relative contribution of leptin vs. insulin signaling in 
these neurons. As mentioned above, leptin inhibits the response of GI neurons to decreased glucose by 
inhibiting AMPK [33]. While insulin has also been reported to inhibit hypothalamic AMPK [64], its 
PI3K-mediated effects on NO production appear to dominate in GI neurons [67]. Thus, insulin might 
be predicted to increase the response to glucose deficit as a result of its stimulatory effect on NO 
production in these neurons [67]. Our data showing that GI neurons are more sensitive to glucose 
deficit in the fasted state when both leptin and insulin levels are low suggest that leptin’s effect on 
AMPK outweighs that of insulin on NO production [33]. However, it remains to be seen whether the 
effect of leptin or insulin resistance will play the dominant role in the function of VMH GI neurons in 
T2DM. The only thing that is clear is that, like GE neurons, GI neurons are regulated by both leptin 
and insulin and therefore one would predict that their function would be altered during the 
hypothalamic leptin and insulin resistance which precedes the development of DIO. 
5. Summary 
In summary, the data provided above support the overall hypothesis that the metabolically sensitive 
VMH glucose sensing neurons serve to protect the brain during times of severe glucose deficit. VMH 
GI and GE neurons are exquisitely sensitive to changes in glucose below euglycemia with little 
response above. VMH NPY-GI neurons become more sensitive to decreased glucose in the fasted 
state. This change in the glucose sensitivity of NPY-GI neurons is correlated with increased NPY 
release in response to decreased glucose. Thus, these data suggest that glucose sensing neurons 
probably evolved to protect the brain during times of famine. Glucose sensing neurons also appear to 
be important for detecting hypoglycemia and generating the CRR. Thus, enhanced detection of glucose 
deficit during famine would also protect against the dangers of hypoglycemia. Moreover, the impaired 
CRR following antecedent hypoglycemia may result, in part, from impairments in the ability of 
glucose sensing neurons to sense glucose decreases. VMH GI and GE neurons clearly have the 
potential to regulate metabolic homeostatic neurocircuitry. In the ARC, 40% of NPY neurons are GI 
neurons. GE neurons are concentrated in the VL-VMN, a region long associated with obesity and 
T2DM. The observation that fasting enhances NPY release in response to decreased glucose suggests 
that the existence of NPY-GI neurons is physiologically significant. Increased NPY neurotransmission 
during fasting would increase food intake and decrease energy expenditure to compensate for energy 
deficit. However, it is important that such powerful homeostatic mechanisms are not called into play 
by small decreases in blood glucose associated with meal to meal changes. Thus, it is logical that leptin 
and insulin prevent GI and GE neurons, respectively, from sensing glucose decreases. Finally, a 
prediction derived from this hypothesis is that glucose sensing neurons are hypersensitive to glucose 
deficit during T2DM. Such enhanced sensitivity would lead the brain to conclude that energy deficit 
existed in the presence of energy sufficiency or even excess. An inappropriate signal of energy deficit 
could lead to compensatory signals contributing to the development or exacerbation of obesity and 
T2DM. The data showing that VL-VMN GE neurons are indeed hypersensitive to glucose decreases in 
T2DM supports this interpretation. Moreover, increased neuronal activity in response to low glucose in 
vivo in T2DM suggests that VMH GI neurons may also be more sensitive to glucose decreases during 
diabetes and obesity [41]. Therefore, taken together, these data suggest that VMH glucose sensing Sensors 2010, 10                                       
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neurons sense glucose deficit. When these neurons “turn a blind eye” to glucose deficit, impairments in 
the CRR result. Similarly, one might predict that disease related anorexia-cachexia might also be 
associated with diminished sensing of glucose decreases. On the other hand, when glucose sensing 
neurons “cry wolf” (e.g., are too sensitive to glucose deficit) the brain misinterprets energy sufficiency 
or even excess and overcompensates. 
While this hypothesis is compelling and well supported by the data presented, a number of 
questions remain. First and foremost, the data linking VMH GI and GE neurons to hypoglycemia 
detection and initiation of the CRR are circumstantial. The direct connections between glucose sensing 
neurons and the autonomic nervous system are not known. It is true that some NPY neurons are GI 
neurons. However, the GI neurons in the VMN are clearly not NPY neurons. It is clear that 
determining the peptide and neurotransmitter phenotype of both VMN GI and VL-VMN GE neurons is 
critical. Though, it is likely that glucose sensing neurons will form heterogenous populations belonging 
to a number of metabolic “emergency” circuits to be called into service when needed. It will also be 
important to determine how glucose sensing neurons become impaired during HAAF and how that 
might be rectified. Even more important is the need to understand how the glucose sensitivity of VMH 
glucose sensing neurons is maintained within a range that allows protection during energy deficit 
without causing overcompensation during energy sufficiency. Resolving these issues will likely lead to 
improved treatments for T1 and T2DM/obesity. 
Finally, it is important to note that this hypothesis pertains only to the metabolically sensitive VMH 
GE and GI neurons. A role for other glucose sensing neurons in daily food intake and energy 
homeostasis remains to be established. What is clear is that VMH GE and GI neurons are not 
responsive to changes in glucose which would occur between meals, especially in the presence of 
insulin and leptin [30-33,48]. However, glucose concentration-response relationships have not been 
determined for other subtypes of glucose sensing neurons. Moreover, it is well established that glucose 
injections towards the brain in vivo increase hypothalamic neuronal activation (i.e., fos-like 
immunoreactivity) [51,120]. Similarly, increased brain glucose leads to insulin secretion [122] and 
inhibits feeding [123]. Thus, the brain is able to detect and respond to increases in glucose above 
euglycemia. This response could be mediated by either neuronal or astrocytic glucose sensors which 
are regulated by glucose metabolism or by sensing the glucose molecule directly[51,122-125]. 
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